Atezolizumab: tested on its own

84 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver ResectionNot yet recruitingNCT07461675Phase 3Report a problem
• Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With AtezolizumabRecruitingNCT06771518Phase 2Report a problem
• Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaRecruitingNCT06492954Phase 1Report a problem
• Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal CarcinomaRecruitingNCT06254911Phase 2Report a problem
• A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialRecruitingNCT06069726Phase 2Report a problem
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1Report a problem
• DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionRecruitingNCT05770102Phase 2/3Report a problem
• Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBRecruitingNCT05295212Phase 2Report a problem
• Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)RecruitingNCT04996017Phase 3Report a problem
• Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLCRecruitingNCT04865250Phase 2Report a problem
• Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCRecruitingNCT04467723Phase 1/2Report a problem
• Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityRecruitingNCT04273061Phase 2Report a problem
• Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)RecruitingNCT03548428Phase 2Report a problem
• A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung CancerCompletedNCT05171777Phase 2Results postedReport a problem
• Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary SiteTerminatedNCT05110781Phase 2Results postedReport a problem
• Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell CarcinomaCompletedNCT04710498Phase 2Results postedReport a problem
• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following CystectomyCompletedNCT04660344Phase 3Results postedReport a problem
• Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck CancerCompletedNCT04477759Phase 1Results postedReport a problem
• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced ChondrosarcomaActive, not recruitingNCT04458922Phase 2Results postedReport a problem
• Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerActive, not recruitingNCT04214262Phase 3Results postedReport a problem
• Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain MetastasisCompletedNCT03526900Phase 2Results postedReport a problem
• Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain MetastasisCompletedNCT03483012Phase 2Results postedReport a problem
• Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular LymphomaTerminatedNCT03465891Phase 2Results postedReport a problem
• A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminatedNCT03452137Phase 3Results postedReport a problem
• A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT03285763Phase 4Results postedReport a problem
• Study of Atezolizumab in Relapsed or Refractory Hodgkin LymphomaTerminatedNCT03120676Phase 2Results postedReport a problem
• Atezolizumab Immunotherapy in Patients With Advanced NSCLCCompletedNCT03102242Phase 2Results postedReport a problem
• A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following NephrectomyTerminatedNCT03024996Phase 3Results postedReport a problem
• Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03014648Phase 2Results postedReport a problem
• A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)CompletedNCT02951767Phase 2Results postedReport a problem
• A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary TractCompletedNCT02928406Phase 3Results postedReport a problem
• A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT02848651Phase 2Results postedReport a problem
• Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerCompletedNCT02844816Phase 2Results postedReport a problem
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid TumorsTerminatedNCT02541604Phase 1/2Results postedReport a problem
• Neoadjuvant Atezolizumab in Localized Bladder CancerCompletedNCT02451423Phase 2Results postedReport a problem
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionTerminatedNCT02450331Phase 3Results postedReport a problem
• A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)TerminatedNCT02409355Phase 3Results postedReport a problem
• A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)CompletedNCT02108652Phase 2Results postedReport a problem
• A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT02031458Phase 2Results postedReport a problem
• A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing TherapyCompletedNCT02008227Phase 3Results postedReport a problem
• A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"CompletedNCT01903993Phase 2Results postedReport a problem
• Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer PatientsWithdrawnNCT06416436Phase 1Report a problem
• Atezolizumab for Idiopathic Pulmonary FibrosisActive, not recruitingNCT05515627Phase 1Report a problem
• A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungActive, not recruitingNCT05470595Phase 2Report a problem
• Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCActive, not recruitingNCT05085496Phase 1Report a problem
• Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCCCompletedNCT05053737Phase 1Report a problem
• A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05047250Phase 3Report a problem
• Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).Status unknownNCT05038657Phase 2Report a problem
• Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHNCompletedNCT04939480Phase 2Report a problem
• A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)CompletedNCT04636762Phase 2Report a problem
• Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerCompletedNCT04624399Phase 2Report a problem
• Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLCTerminatedNCT04549428Phase 2Report a problem
• Thoracic RadiothErapy with Atezolizumab in Small Cell LUng CanceR Extensive DiseaseCompletedNCT04462276Phase 2Report a problem
• A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic CarcinomaCompletedNCT04321330Phase 2Report a problem
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2Report a problem
• Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideCompletedNCT04221529Phase 2Report a problem
• Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncerActive, not recruitingNCT04186013Phase 2Report a problem
• Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical CystectomyActive, not recruitingNCT04138628Phase 2Report a problem
• Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]CompletedNCT04059887Phase 4Report a problem
• Neoadjuvant Atezolizumab in Cutaneous MelanomaActive, not recruitingNCT04020809Phase 1Report a problem
• Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)CompletedNCT03976518Phase 2Report a problem
• A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03922997Phase 3Report a problem
• A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural MesotheliomaWithdrawnNCT03786419Phase 2Report a problem
• Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical CystectomyActive, not recruitingNCT03697850Phase 2Report a problem
• Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLCTerminatedNCT03644823Phase 2Report a problem
• Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder CancerStatus unknownNCT03620435Phase 2Report a problem
• SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical CancerActive, not recruitingNCT03614949Phase 2Report a problem
• The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder CancerStatus unknownNCT03577132Not applicableReport a problem
• Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung CancerActive, not recruitingNCT03540420Phase 2Report a problem
• Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast CancerCompletedNCT03464942Phase 2Report a problem
• The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCLActive, not recruitingNCT03463057Phase 2Report a problem
• PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03357224Phase 2Report a problem
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboActive, not recruitingNCT03281954Phase 3Report a problem
• Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLCStatus unknownNCT03262454Phase 2Report a problem
• Immunotherapy as Second-line in Patient With Small Cell Lung CancerCompletedNCT03059667Phase 2Report a problem
• Atezolizumab as Induction Therapy in Non-small Cell Lung CancerCompletedNCT02994576Phase 2Report a problem
• Atezolizumab in Treating Patients With Cancer Following Adoptive Cell TransferActive, not recruitingNCT02862275Phase 1Report a problem
• Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaTerminatedNCT02784483Phase 1Report a problem
• Preoperative MPDL3280A in Transitional Cell Carcinoma of the BladderCompletedNCT02662309Phase 2Report a problem
• Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT02599454Phase 1Report a problem
• MPDL3280A-treatment-IST-UMCGActive, not recruitingNCT02478099Phase 2Report a problem
• A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLCCompletedNCT02463994Early Phase 1Report a problem
• MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung CancerTerminatedNCT02400814Phase 1Report a problem
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01375842Phase 1Report a problem

← Atezolizumab